- Home
- SB vs MREO Comparison
SB vs MREO Comparison
Compare SB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- MREO
- Stock Information
- Founded
- SB 2007
- MREO 2015
- Country
- SB Monaco
- MREO United Kingdom
- Employees
- SB N/A
- MREO N/A
- Industry
- SB Marine Transportation
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- SB Consumer Discretionary
- MREO Health Care
- Exchange
- SB Nasdaq
- MREO Nasdaq
- Market Cap
- SB 395.3M
- MREO 369.2M
- IPO Year
- SB 2008
- MREO N/A
- Fundamental
- Price
- SB $3.75
- MREO $2.30
- Analyst Decision
- SB Strong Buy
- MREO Strong Buy
- Analyst Count
- SB 1
- MREO 7
- Target Price
- SB $6.00
- MREO $7.71
- AVG Volume (30 Days)
- SB 624.1K
- MREO 1.3M
- Earning Date
- SB 04-28-2025
- MREO 03-26-2025
- Dividend Yield
- SB 5.32%
- MREO N/A
- EPS Growth
- SB 36.11
- MREO N/A
- EPS
- SB 0.83
- MREO N/A
- Revenue
- SB $307,633,000.00
- MREO N/A
- Revenue This Year
- SB N/A
- MREO N/A
- Revenue Next Year
- SB $14.32
- MREO $69.09
- P/E Ratio
- SB $4.53
- MREO N/A
- Revenue Growth
- SB 8.17
- MREO N/A
- 52 Week Low
- SB $3.31
- MREO $2.23
- 52 Week High
- SB $6.33
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- SB 50.71
- MREO 36.53
- Support Level
- SB $3.70
- MREO $2.23
- Resistance Level
- SB $3.82
- MREO $2.73
- Average True Range (ATR)
- SB 0.08
- MREO 0.14
- MACD
- SB -0.01
- MREO -0.00
- Stochastic Oscillator
- SB 50.00
- MREO 14.85
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).